Oracle Rallies 5% as Morgan Stanley Lifts Its Price Target, CoreWeave Advances 3%
π Oracle stock rallied 5% to $167.15 following a Morgan Stanley price target raise that validated the AI infrastructure spending case.
βοΈ Cloud Infrastructure revenue grew 93% year-over-year to $5.79 billion in Q4 FY2026, driven by strong GPU adoption.
π Remaining Performance Obligations surged 363% to $638 billion, with $75 billion specifically tied to prepaid or customer-supplied GPU AI contracts.
π― Management confirmed a $90 billion FY2027 revenue target and raised non-GAAP EPS guidance to $8.05.
π° Oracle plans to raise approximately $40 billion through debt and equity in FY2027 to fund its aggressive expansion.
βοΈ Free cash flow was negative $23.7 billion for FY2026 due to $55.7 billion in capital expenditures on AI infrastructure.
π Oracle shares are down 14% year-to-date, making today's rally a recovery move off a weak annual performance.
π The Morgan Stanley re-rating indicates sell-side analysts are now willing to underwrite the company's heavy capital plan.
ποΈ The next key catalyst is Oracle's Q1 FY2027 earnings release scheduled for September 2, which will test RPO trajectory.
- Morgan Stanley raised its price target, validating the market's AI infrastructure spending case and lifting sentiment around Oracle's cloud pipeline.
- Cloud Infrastructure revenue surged 93% year-over-year to $5.79 billion in Q4 FY2026, demonstrating strong demand for GPU AI contracts.
- Remaining Performance Obligations jumped 363% to $638 billion, including $75 billion tied to prepaid or customer-supplied GPU AI contracts.
- Management confirmed a robust $90 billion FY2027 revenue target and raised non-GAAP EPS guidance to $8.05.
- The sell-side re-rating signals analyst confidence that Oracle can execute its capital plan against expected AI cloud revenue growth.
- Free cash flow was negative $23.7 billion for FY2026, driven by heavy $55.7 billion in capital expenditures.
- Oracle plans to raise approximately $40 billion through debt and equity in FY2027, which remains a bear case concern for shareholders.
- Shares are down 14% year-to-date, indicating the stock has underperformed despite recent positive catalysts.
- The next earnings report on September 2 is a critical test; any deceleration in RPO trends could challenge the multiple Morgan Stanley is now willing to pay.